Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
These phase 3 trial results point to little benefit to current EGFR-targeted agents in an unselected patient population, and highlight the need for predictive biomarkers in the treatment of esophageal cancer.
|
28687830 |
2017 |
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Northern blot analysis revealed a fourfold increase (p < 0.01) in EGF-R mRNA levels in the esophageal cancer samples in comparison with normal tissue samples.
|
10512940 |
1999 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
The selection of esophageal cancer patients for future studies with EGFR-TKIs based on the level of EGFR expression in their tumors or SCC histology should be considered.
|
16575012 |
2006 |
Malignant neoplasm of esophagus
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer.
|
23377570 |
2014 |
Malignant neoplasm of esophagus
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These data suggest that EGF-R and p53 mutation may be used as both outcome predictors and targets for molecular therapy for esophageal cancer.
|
14695149 |
2003 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
While more primary esophageal tumors remain to be screened for the mutations at the tyrosine kinase domain of EGFR, current observation implies that gefitinib may be worth further investigation for treatment of esophageal cancers.
|
16357520 |
2006 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
CTD_human |
Targeting the human EGFR family in esophagogastric cancer.
|
21468131 |
2011 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR), the efficacy of nimotuzumab added to nCRT for esophageal cancer is uncertain.
|
31258850 |
2019 |
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this report, the effect of PYM on EGFR expression in human esophageal cancer cells and the therapeutic efficacy of the combination of PYM and cetuximab on esophageal cancer xenograft were investigated.
|
22311160 |
2012 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
CTD_human |
The EGFR CA repeat genetic polymorphism may act as a valuable molecular predictor of clinical outcome of esophageal cancer after CCRT and esophagectomy, especially in those with good response to CCRT.
|
21298351 |
2011 |
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This cancer-targeted design of Se NPs provides a new strategy for synergistic treating of cancer with higher efficacy and reduced side effects, introducing GE11-Ori-Se NPs as a candidate for further evaluation as a chemotherapeutic agent for EGFR over-expressed esophageal cancers.
|
29019267 |
2017 |
Malignant neoplasm of esophagus
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that enhanced transcription of the epidermal growth factor receptor gene is associated with the development of some esophageal cancers.
|
3044581 |
1988 |
Malignant neoplasm of esophagus
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Mutations of EGFR were identified in two esophageal cancers (11.7%), three cases of Barrett's esophagus (14.2%), and two pancreatic cancers (3.6%).
|
16857803 |
2006 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
CTD_human |
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
|
22042947 |
2011 |
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Thus, changes in gene copy number or level of expression of HER-I or c-myc DNA sequences may play an important role in the pathogenesis of esophageal cancer in this high-risk region.
|
2459070 |
1988 |
Malignant neoplasm of esophagus
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Real-time quantitative polymerase chain reaction technology (RT-PCR) was used to detect the expression of VEGF, HER-2, and EGFR mRNA in esophageal squamous cancer tissue of 60 cases and 30 cases of VEGF, HER-2, and EGFR mRNA in esophageal cancer adjacent tissues, and analyze its relationship with clinicopathological features.
|
26099724 |
2015 |
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Results indicated that PT shows more effective antitumor activity as compared with Pan both on EGFR-overexpressed KYSE-450 and KYSE-150 esophageal cancer cells, especially on KYSE-450 cells.
|
30596104 |
2018 |
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We report the outcome in a series of esophageal cancer patients treated at our center and the results of a retrospective analysis of epidermal growth factor receptor (EGFR) expression and EGFR/HER2 gene copy numbers taken as possible prognostic and predictive factors.
|
23052161 |
2012 |
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this study, we first evaluated EGFR gene and protein expression in 70 Chinese EC patient tumor samples collected during surgery.
|
28881608 |
2017 |
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We also observed a significant increase in ERCC1 expression, and decrease in p53 and EGFR expression, in EC-9706 cells treated with SNX-2112 (P < 0.05), indicating the regulation of EC by SNX-2112.
|
27420968 |
2016 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
The int-2 and erbB genes are amplified more frequently than any other genes in human esophageal cancer.
|
9316622 |
1997 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
To evaluate which molecular biological factors are related to patients' prognosis and recurrence, we checked p53, p16, p21/Waf1, cyclin D1, Ki-67, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), Mdm2, Bcl2, E-cadherin and MRP1/CD9 by means of immunohistochemical analysis in 116 cases of oesophageal cancer (R0).
|
10376985 |
1999 |
Malignant neoplasm of esophagus
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Gene-gene interaction of EGFR 497Arg>Lys and EGF +61A>G polymorphisms enhanced risk for EC, indicating additive effects.
|
18773861 |
2008 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
|
21207425 |
2011 |